Positive Outcome From FORTE Basket Study of Plixorafenib Monotherapy in Recurrent or Progressive BRAF V600 Primary CNS Tumors Announced
“We are very pleased that the BRAF V600 primary CNS basket of the FORTE study has passed the protocol-specified interim analysis supporting that tumor regressions in patients treated with plixorafenib continue to be observed,” said Stacie Peacock Shepherd, M.D., Ph.D., Chief Medical Officer of Fore. “We believe this is an encouraging development for the study, and more importantly, for patients in need of novel treatment options for recurrent primary CNS tumors. The data with this novel BRAF inhibitor, known as a paradox breaker, builds on the recent momentum for the potential of plixorafenib to benefit patients across BRAF-altered solid tumors, including the recent presentation of encouraging data in patients with BRAF-altered thyroid cancers, which has generated significant enthusiasm in the field. This significant milestone builds upon the validated approach of targeting BRAF, while avoiding the limitations of the earlier generation compounds that led to rapid recurrence of disease and the need for combination with a MEK inhibitor, and brings us one step closer to our objective of accelerating access to adults and children diagnosed with recurrent BRAF-altered brain or spinal cord tumors. We look forward to completing enrollment and reporting topline results from this registrational CNS basket in the second half of 2026.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the